Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib

Cover Page

Cite item

Full Text

Abstract

Over the past two decades, many new variants of targeted therapy for metastatic colorectal cancer (mCRC) had appeared, and significantly increased patient survival. However, there were questions relating to the definition of the optimal sequence and the combination of different drugs. Cytotoxic agents, including irinotecan, oxaliplatin, 5-fluorouracil and capecitabine, are the basis of the treatment of mCRC. In addition, the arsenal of modern oncologist includes the group of drugs inhibiting the epidermal growth factors (for example, cetuximab and panitumumab) and inhibiting tumor angiogenesis factors (for example, bevacizumab and aflibercept). Moreover, the use of immuno-oncology drugs, trastuzumab or encorafenib is possible in case of knowing tumor-specific molecular signature. Unfortunately, these new indications can be used only in small proportion of patients. The multikinase inhibitor regorafenib takes a special place, it can be used in patients in spite of RAS mutation status. The increasing attention has been paid to the selection of the drugs for sequential therapy of mCRC, recently. This review discusses important clinical data on the direct role of targeted drugs in the treatment of mCRC in different subgroups of patients.

About the authors

M. I. Sekacheva

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: sekach_rab@mail.ru
ORCID iD: 0000-0003-0015-7094

D. Sci. (Med.), Prof., Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

R. I. Nuriev

Sechenov First Moscow State Medical University (Sechenov University)

Email: sekach_rab@mail.ru

Graduate Student, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

A. A. Rozhkov

Sechenov First Moscow State Medical University (Sechenov University)

Email: sekach_rab@mail.ru

Resident, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

A. V. Semenkov

Sechenov First Moscow State Medical University (Sechenov University)

Email: semenkov@inbox.ru
ORCID iD: 0000-0002-7365-6081
Scopus Author ID: 39362227000

D. Sci. (Med.), Prof., Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

N. N. Bagmet

Petrovsky Russian Scientific Center of Surgery

Email: bagmetn@mail.ru
ORCID iD: 0000-0001-8325-4409

D. Sci. (Med.), Petrovsky Russian Scientific Center of Surgery

Russian Federation, Moscow

A. M. Boroda

Sechenov First Moscow State Medical University (Sechenov University)

Email: alex.boroda@lenta.ru
ORCID iD: 0000-0002-4196-6042
Scopus Author ID: 56485884100

Research Officer, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

References

  1. Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. Therc Advanc Med Oncol 2017; 9 (8): 551–64.
  2. Miyamoto Y, Suyama K, Baba H. Recent advances in targeting the EGFR signaling pathway for the treatment of metastatic colorectal cancer. Int J Mol Sci 2017; 18 (4): 752.
  3. Meric-Bernstam F, Hurwitz H, Raghav KP et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019; 20 (4): 518–30.
  4. Kopetz S, McDonough SL, Lenz HJ et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).
  5. Ciombor KK, Bekaii‐Saab T. A comprehensive review of sequencing and combination strategies of targeted agents in metastatic colorectal cancer. The oncologist. 2018; 23 (1): 25.
  6. Goldstein DA, Zeichner SB, Bartnik CM et al. Metastatic colorectal cancer: a systematic review of the value of current therapies. Clin Colorectal Cancer 2016; 15 (1): 1–6.
  7. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27 (8): 1386–422.
  8. Venook AP, Niedzwiecki D, Lenz HJ et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. Jama 2017; 317 (23): 2392–401.
  9. Marques RP, Duarte GS, Sterrantino C et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Critic Rev Oncol/Hematol 2017; 118: 54–62.
  10. Eisterer W, Prager G. Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer? Cardiovasc Int Radiol 2019; p. 1–8.
  11. Stintzing S, Modest DP, Rossius L et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016; 17 (10): 1426–34.
  12. Fornasier G, Francescon S, Baldo P. An update of efficacy and safety of cetuximab in metastatic colorectal cancer: a narrative review. Advanc Ther 2018; 35 (10): 1497–509.
  13. Modest DP, Martens UM, Riera-Knorrenschild J et al. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). J Clin Oncol 2019; 37 (35): 3401–11.
  14. Schmieder R, Hoffmann J, Becker M et al. Regorafenib (BAY 73–4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. J Int du Cancer 2014; 135: 1487–96.
  15. Grothey A, Falcone A, Humblet Y et al. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months. J Clin Oncol 2015; 33: 710.
  16. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–12.
  17. Ricotta R, Verrioli A, Ghezzi S et al. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). ESMO Open 2017; 1: e000111.
  18. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619–29.
  19. Tougeron D, de la Fouchardiere C, Etienne PL et al. REBECCA: A large cohort study of Regorafenib (REG) in the real-life setting in patients (pts) previously treatment for metastatic colorectal cancer (mCRC). Eur Soc Med Oncol 2014. Madrid, Spain 2014.
  20. Van Cutsem E, Ciardiello F, Hofheinz R et al. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. ESMO World Congress on Gastrointestinal Cancer 2015. Barcelona, Spain. Ann Oncol 2015; p. iv118.
  21. Cannarile MA, Weisser M, Jacob W et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 2017; 5 (1): 53.
  22. Fukuoka S, Hara H, Takahashi N et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603) [ASCO abstract 2522]. J Clin Oncol 2019; 37 (Suppl. 15).
  23. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350–6.
  24. Dienstmann R, Vermeulen L, Guinney J et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017; 17: 79–92.
  25. Teufel M, Schwenke S, Seidel H et al. Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. ASCO 2015. Chicago, Illinois, USA; 2015.
  26. Bhadkamkar NA, Sahin IH, Shen Y et al. Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure. ASCO Meet Abst 2013; 31: 500.
  27. Townsend AR, Bishnoi S, Broadbridge V et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol 2013; 36: 49–52.
  28. Chibaudel B, Tournigand C, Bonnetain F et al. Platinum-sensitivity in metastatic colorectal cancer: towards a definition. Eur J Cancer 2013; 49: 3813–20.
  29. Arena S, Bellosillo B, Siravegna G et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015; 21: 2157–66.
  30. Siravegna G, Mussolin B, Buscarino M et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21: 827.
  31. Bertocchi P, Aroldi F, Prochilo T et al. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope? J Chemother 2017; 29 (2): 102–5.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies